NCT05646836

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of XmAb24306 in Combination With Cevostamab in Participants With Relapsed/Refractory Multiple Myeloma

A Phase Ib, Open-label, Multicenter Dose-escalation Study to Evaluate the Safety, Pharmacokinetics, and Activity of XmAb24306 in Combination With Cevostamab in Patients With Relapsed/Refractory Multiple Myeloma

• Status: Active Not Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 90 (estimated)
• Sponsor: Genentech, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and activity of XmAb24306 in combination with cevostamab in participants with relapsed/refractory multiple myeloma (R/R MM) who have received a minimum of three prior treatments, including at least one immunomodulatory drug (IMiD), one proteasome inhibitor (PI), and one anti-CD38 monoclonal antibody.

Conditions

• Multiple Myeloma

Interventions

Type	Name	Description
DRUG	Cevostamab	Cevostamab will be administered intravenously on a 28-day cycle, for up to one year of treatment depending on clinical response.
DRUG	XmAb24306	XmAb24306 will be administered intravenously on a 28-day cycle, for up to one year of treatment depending on clinical response.
DRUG	Tocilizumab	Tocilizumab will be administered for the treatment of cytokine release syndrome (CRS) when necessary.

Timeline

• Start date: 2023-03-21
• Primary completion: 2026-11-18
• Completion: 2026-11-18
• First posted: 2022-12-12
• Last updated: 2026-02-17

Locations

13 sites across 7 countries: Australia, Denmark, Greece, Israel, Norway, South Korea, Spain